Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

21.21+1.04+5.16%Vol 16.66K1Y Perf -22.45%
Aug 11th, 2022 15:35 DELAYED
BID21.10 ASK21.31
Open20.19 Previous Close20.16
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     50.67
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★★     59.51
Price Range Ratio 52W %
44.61 
Earnings Rating
Market Cap21.21M 
Earnings Date
-
Alpha0.00 Standard Deviation0.08
Beta0.96 

Today's Price Range

20.1921.36

52W Range

16.8626.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
8.24%
1 Month
10.79%
3 Months
0.88%
6 Months
-17.20%
1 Year
-22.45%
3 Years
-1.51%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FBIOP21.211.04105.16
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
53.70
-217.30
-208.20
-282.90
-
RevenueValueIndustryS&P 500US Markets
63.29M
18.47
22.07
-6.86
DividendsValueIndustryS&P 500US Markets
12.95
2.34
0.00
-
Payout ratio-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume16.66K
Shares Outstanding1.00K
Shares Float3.43M
Trades Count97
Dollar Volume351.32K
Avg. Volume8.94K
Avg. Weekly Volume5.18K
Avg. Monthly Volume7.78K
Avg. Quarterly Volume13.85K

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) stock closed at 21.205 per share at the end of the most recent trading day (a 5.16% change compared to the prior day closing price) with a volume of 16.66K shares and market capitalization of 21.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock CEO is Lindsay A. Rosenwald.

The one-year performance of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock is -22.45%, while year-to-date (YTD) performance is -18.06%. FBIOP stock has a five-year performance of %. Its 52-week range is between 16.8601 and 26.6, which gives FBIOP stock a 52-week price range ratio of 44.61%

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 0.98, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -18.44%, a ROC of -29.64% and a ROE of -72.42%. The company’s profit margin is -%, its EBITDA margin is -208.20%, and its revenue ttm is $63.29 Million , which makes it $18.47 revenue per share.

Of the last four earnings reports from Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock’s next earnings report date is -.

The consensus rating of Wall Street analysts for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has a dividend yield of 12.95% with a dividend per share of $2.34 and a payout ratio of -%.

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has a Buy technical analysis rating based on Technical Indicators (ADX : 15.37, ATR14 : 0.42, CCI20 : 168.16, Chaikin Money Flow : 0.07, MACD : 0.32, Money Flow Index : 89.08, ROC : 7.60, RSI : 66.80, STOCH (14,3) : 91.14, STOCH RSI : 1.00, UO : 64.36, Williams %R : -8.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

CEO: Lindsay A. Rosenwald

Telephone: +1 781 652-4500

Address: 2 Gansevoort Street, New York 10014, NY, US

Number of employees: 93

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

64%36%


News

Stocktwits